Arlington, MA – According to filings with the U.S. Securities and Exchange Commission, Tetragenetics is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Douglas Kahn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Tetragenetics

TetraGenetics harnesses the unique capabilities of the protozoa Tetrahymena thermophila to produce recombinant proteins for use in the discovery of novel antibody therapeutics targeting membrane proteins implicated in numerous human diseases. With our world-renowned science team, we are developing large molecule drugs for autoimmune diseases, pain, respiratory diseases, and oncology.

To learn more about Tetragenetics, visit http://www.tetragenetics.com/

Contact:
Douglas Kahn, Chief Executive Officer
617-500-7471
dkahn@tetragenetics.com
https://www.linkedin.com/in/doug-kahn-25a57b9/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved